| Unique ID issued by UMIN | UMIN000052758 |
|---|---|
| Receipt number | R000060201 |
| Scientific Title | The Effects of Ginger Extract Beverage on Nausea, Vomiting, and Nutritional Status in Chemotherapy-treated Cancer Patients |
| Date of disclosure of the study information | 2024/12/31 |
| Last modified on | 2023/11/10 15:59:50 |
The Effects of Ginger Extract Beverage on Nausea, Vomiting, and Nutritional Status in Chemotherapy-treated Cancer Patients
Nutritional Supplements for Prevention of Nausea and Vomiting
The Effects of Ginger Extract Beverage on Nausea, Vomiting, and Nutritional Status in Chemotherapy-treated Cancer Patients
Study of Nutraceutical Beverage with Ginger Extract for Prevention of Nausea and Vomiting
| Japan |
cancer
| Medicine in general |
Malignancy
NO
To investigate the effects on nausea and vomiting in hospitalized lung cancer patients who consume a dietary supplement drink (Isocal Clear) containing ginger extract from 3 days before to 7 days after chemotherapy.
Efficacy
Confirmatory
Phase IV
Complete response (CR)
*CR is defined as nausea of 0 at NRS, no emetic events, and no emergency antiemetic use.
1) Nausea
2) Vomiting event
3) Urgent use of antiemetic drugs
4) Weight change
5) Compliance with intake (intervention group only)
Observational
| 20 | years-old | <= |
| Not applicable |
Male and Female
1) Patients with head and neck cancer, gynecological cancer, and lung cancer eligible for NST intervention who are hospitalized in our hospital
2) Patients 20 years of age or older
3) Patients who have undergone chemotherapy for cancer within 1 month prior to obtaining consent and have CTCAEv4.0-JCOG Grade 2 or higher nausea (marked weight loss, dehydration or decreased oral intake without malnutrition)
4) Patients scheduled to receive chemotherapy during hospitalization
(5) Patients who are able to eat and drink orally.
6) Patients who are able to obtain written consent.
(1) Patients whose chemotherapy within 1 month prior to obtaining consent and whose planned chemotherapy is expected to change
(2) Patients who are expected to change their chemotherapy antiemetic regimen within 1 month prior to obtaining consent and their scheduled chemotherapy antiemetic regimen.
(3) Patients who are deemed inappropriate as research subjects by the Principal Investigator and the Principal Investigator.
15
| 1st name | Hiroshi |
| Middle name | |
| Last name | Sakaue |
Tokushima University Graduate School
Department of Nutrition and Metabolism, Institute of Biomedical sciences
7708503
3-18-15 Kuramoto-cho, Tokushima 770-8503
0886339249
hsakaue@tokushima-u.ac.jp
| 1st name | Hiorhshi |
| Middle name | |
| Last name | Sakaue |
Tokushima University Graduate School
Department of Nutrition and Metabolism, Institute of Biomedical sciences
770-8503
3-18-15 Kuramoto-cho, Tokushima 770-8503
0886339249
hsakaue@tokushima-u.ac.jp
Department of Nutrition and Metabolism, Institute of Biomedical sciences
Tokushima University Graduate School
Department of Nutrition and Metabolism, Institute of Biomedical sciences
Tokushima University Graduate School
Self funding
The Ethics Committee of Tokushima University Hospital
2-50-1 Kuramoto-cho, Tokushima
0886339295
awachiken@tokushima-u.ac.jp
NO
徳島大学
| 2024 | Year | 12 | Month | 31 | Day |
Unpublished
Preinitiation
| 2023 | Year | 11 | Month | 01 | Day |
| 2023 | Year | 11 | Month | 01 | Day |
| 2024 | Year | 10 | Month | 31 | Day |
None noted
| 2023 | Year | 11 | Month | 10 | Day |
| 2023 | Year | 11 | Month | 10 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000060201